- Trials with a EudraCT protocol (148)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
148 result(s) found for: Left ventricle.
Displaying page 7 of 8.
EudraCT Number: 2018-004655-20 | Sponsor Protocol Number: LIGHT | Start Date*: 2019-05-30 | |||||||||||
Sponsor Name:HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS | |||||||||||||
Full Title: CLINICAL EFFICACY OF INHIBITION OF ORGAN DYSFUNCTION THROUGH BERMEKIMAB IN SYSTEMIC SCLEROSIS: A PROOF-OF-CONCEPT DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL (THE LIGHT TRIAL) | |||||||||||||
Medical condition: CLINICAL EFFICACY OF INHIBITION OF ORGAN DYSFUNCTION THROUGH BERMEKIMAB IN SYSTEMIC SCLEROSIS: A PROOF-OF-CONCEPT DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL (THE LIGHT TRIAL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002113-64 | Sponsor Protocol Number: CLCZ696BFI03 | Start Date*: 2017-11-27 |
Sponsor Name:Novartis Finland Oy | ||
Full Title: Controlled trial on the short-term effects of sacubitril/valsartan therapy on cardiac oxygen consumption and efficiency of cardiac work in patients with NYHA II-III heart failure and reduced systol... | ||
Medical condition: NYHA II-III heart failure and reduced systolic function | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002643-28 | Sponsor Protocol Number: CA209-8JD | Start Date*: 2019-02-25 | |||||||||||
Sponsor Name:Amsterdam UMC, location VUmc | |||||||||||||
Full Title: Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction. | |||||||||||||
Medical condition: Stage III/IV resectable oral squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001494-24 | Sponsor Protocol Number: AK2015-10 | Start Date*: 2018-06-26 | |||||||||||
Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET | |||||||||||||
Full Title: In vivo molecular imaging of angiogenesis after VEGF-D gene therapy | |||||||||||||
Medical condition: Ischemic heart disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002400-20 | Sponsor Protocol Number: 81866 | Start Date*: 2023-02-28 | |||||||||||
Sponsor Name:Amsterdam UMC, location VUmc | |||||||||||||
Full Title: Feasibility of empagliflozin as treatment for idiopathic pulmonary arterial hypertension | |||||||||||||
Medical condition: Idiopathic Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003797-23 | Sponsor Protocol Number: KKS-305 | Start Date*: 2023-05-16 | ||||||||||||||||||||||||||
Sponsor Name:Philipps University Marburg | ||||||||||||||||||||||||||||
Full Title: Myeloperoxidase inhibition in patients with ischemic or non-ischemic cardiomyopathy and heart failure with reduced ejection fraction | ||||||||||||||||||||||||||||
Medical condition: Ischemic or non-ischemic cardiomyopathy and heart failure with reduced ejection fraction. Danke | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002305-38 | Sponsor Protocol Number: 2013CV11 | Start Date*: 2015-01-21 | ||||||||||||||||||||||||||
Sponsor Name:University of Dundee/ NHS Tayside | ||||||||||||||||||||||||||||
Full Title: Does allopurinol reduce right ventricular mass in lung disease associated pulmonary hypertension? | ||||||||||||||||||||||||||||
Medical condition: right ventricular hypertrophy associated with COPD or Interstitial Lung Disease and pulmonary hypertension | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-002678-21 | Sponsor Protocol Number: APO-Peg-03 | Start Date*: 2012-01-10 | |||||||||||
Sponsor Name:Apotex Inc | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, ACTIVE CONTROLLED, ASSESSORBLINDED STUDY OF SAFETY AND EFFICACY OF PEGYLATED APOFILGRASTIM VERSUS US AND EU LICENSED NEULASTA® IN SUBJECTS WITH STAGE IIA, IIB OR IIIA BREA... | |||||||||||||
Medical condition: Febrile neutropenia in breast cancer patients undergoing TAC chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) BG (Completed) GR (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022695-31 | Sponsor Protocol Number: 20110204 | Start Date*: 2011-04-12 | ||||||||||||||||
Sponsor Name:Karolinska Institute, Södersjukhuset AB | ||||||||||||||||||
Full Title: Effects on subclinical heartfailure in type 2 diabetic subjects on liraglutide treatment versus glimepiride both in combination with metformin. | ||||||||||||||||||
Medical condition: Type 2 diabetes mellitus and sublinical heart failure | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000266-64 | Sponsor Protocol Number: PEGF/USV/P3/003 | Start Date*: 2015-06-18 | ||||||||||||||||
Sponsor Name:USV Limited | ||||||||||||||||||
Full Title: A Randomised, Multi-Centre, Assessor-Blinded, Active-Controlled, Parallel Group, Equivalence Phase III Study Comparing the Safety and Efficacy of USV Pegfilgrastim and Neulasta® in Breast Cancer Pa... | ||||||||||||||||||
Medical condition: Duration of Sever Neutropenia and incidence of febrile neutropenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: HU (Completed) BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-001578-27 | Sponsor Protocol Number: ABX464-302 | Start Date*: 2019-10-15 | |||||||||||
Sponsor Name:Abivax | |||||||||||||
Full Title: A follow-up Phase 2a open-label study to evaluate the long-term safety and efficacy profile of ABX464 in patients with moderate to severe active Rheumatoid Arthritis. | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003817-42 | Sponsor Protocol Number: NILG-AML 02/06 | Start Date*: 2006-09-11 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE | |||||||||||||
Full Title: A phase III trial in adult acute myelogenous leukemia AML comparing 1 standard-dose versus high-dose remission induction therapy and 2 , within a risk-oriented postremission strategy, an autolo... | |||||||||||||
Medical condition: PATIENT WHIT LMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002213-60 | Sponsor Protocol Number: GX1001 | Start Date*: 2019-01-08 | ||||||||||||||||
Sponsor Name:Solid Biosciences Inc. | ||||||||||||||||||
Full Title: A randomized, controlled, open-label, single-ascending dose, phase I/II study to investigate the safety and tolerability, and efficacy of intravenous SGT-001 in male adolescents and children with D... | ||||||||||||||||||
Medical condition: Duchenne muscular dystrophy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001900-39 | Sponsor Protocol Number: 11/0475 | Start Date*: 2012-11-01 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: A multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin plus Rituximab and CVP (IO-R-CVP) versus Gemcitabine plus Rituximab and CVP (Gem-R-CVP) for the first line treatment of pat... | |||||||||||||
Medical condition: Diffuse large B cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000303-42 | Sponsor Protocol Number: 9050 | Start Date*: 2006-09-25 | |||||||||||
Sponsor Name:ISALA KLINIEKEN | |||||||||||||
Full Title: A randomized, double blind controlled trial evaluating the benefits of early up-front-loaded high dose Tirofiban in the treatment of patients with ST-segment elevation myocardial infarction, who ar... | |||||||||||||
Medical condition: acute myocardial infarction with ST segment elevation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001466-37 | Sponsor Protocol Number: A-STAMI | Start Date*: 2021-07-08 | ||||||||||||||||
Sponsor Name:Västra Götalandsregionen, Sahlgrenska University Hospital | ||||||||||||||||||
Full Title: Adenosine’s effect on STunning resolution in Acute Myocardial Infarction | ||||||||||||||||||
Medical condition: Acute Myocardial Infarction | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004730-34 | Sponsor Protocol Number: 361.11 | Start Date*: 2011-07-20 | |||||||||||
Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA | |||||||||||||
Full Title: A phase II multicentre, randomized, controlled open-label study on the use of anti-thymocyte globulin and rituximab for immunomodulation of graft-versus-host disease in allogeneic matched transpla... | |||||||||||||
Medical condition: graft-versus-host disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004317-24 | Sponsor Protocol Number: MN2015-1/A | Start Date*: 2017-06-22 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI | |||||||||||||
Full Title: “A pilot study to assess Coronary Flow Reserve and post-vasodilatatory Myocardial Blood Flow (post-Dipi gMBF), measured by 13N-NH3 PET/CT, before and after a six months-long treatment with the AC... | |||||||||||||
Medical condition: Hypertrophic Cardiomyopathy (primitive) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001962-25 | Sponsor Protocol Number: BR1-142 | Start Date*: 2016-03-04 | |||||||||||
Sponsor Name:Bracco Imaging S.p.A. | |||||||||||||
Full Title: A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress Echocardiography with Dobutamine for the Diagnosis ... | |||||||||||||
Medical condition: Suspected or known Coronary Artery Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000044-18 | Sponsor Protocol Number: GEM2017FIT | Start Date*: 2018-07-04 | |||||||||||
Sponsor Name:Fundación PETHEMA | |||||||||||||
Full Title: Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab, 18 ... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
